Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome-Reference-Cited by-同舟云学术

Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome

Published:2021-01-09 Issue:7 Volume:100 Page:1711-1722
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Subirá Dolores^ORCID,Alhan Canan,Oelschlaegel Uta,Porwit Anna,Psarra Katherina,Westers Theresia M.,Golbano Nuria,Nilsson Lars,van de Loosdrecht Arjan A,de Miguel Dunia

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-021-04411-4.pdf

Reference35 articles.

1. Valent P, Orazi A, Steensma DP, et al (2017) Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget 8:73483–73500. 10.18632/oncotarget.19008

2. Platzbecker U (2019) Treatment of MDS. Blood 133:1096–1107. https://doi.org/10.1182/blood-2018-10-844696

3. van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SSC, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VHJ, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM (2013) Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 54:472–475. https://doi.org/10.3109/10428194.2012.718341

4. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VHJ, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA (2012) Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 26:1730–1741. https://doi.org/10.1038/leu.2012.30

5. Dimopoulos K, Hansen OK, Sjö LD, et al (2019) The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): a single-center analysis of 79 patients. Cytom Part B - Clin Cytom 250–258. https://doi.org/10.1002/cyto.b.21842

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EXPRESSION PROFILE OF SOME MARKERS OF LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA;Oncology;2023

2. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues;Cytometry Part B: Clinical Cytometry;2022-12-20

3. Immunophenotypic changes in juvenile myelomonocytic leukaemia after treatment with hypomethylating agent: Do they help to evaluate dept of response?;British Journal of Haematology;2022-02-21

4. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group;Cytometry Part B: Clinical Cytometry;2021-12-13

5. Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine;Journal of Clinical Medicine;2021-10-20